{"organizations": [], "uuid": "f2c74657e9ab8333d8a4d5b85bc2e95a65697e02", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shire-says-granted-orphan-drug-sta/brief-shire-says-granted-orphan-drug-status-for-crohns-disease-treatment-for-children-idUSFWN1Q30TS", "country": "US", "domain_rank": 408, "title": "Shire Says Granted Orphan Drug Status For Crohn's Disease Treatment For Children", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.114, "site_type": "news", "published": "2018-02-13T20:08:00.000+02:00", "replies_count": 0, "uuid": "f2c74657e9ab8333d8a4d5b85bc2e95a65697e02"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shire-says-granted-orphan-drug-sta/brief-shire-says-granted-orphan-drug-status-for-crohns-disease-treatment-for-children-idUSFWN1Q30TS", "ord_in_thread": 0, "title": "Shire Says Granted Orphan Drug Status For Crohn's Disease Treatment For Children", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "shire plc", "sentiment": "negative"}, {"name": "shire", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "shire says granted orphan drug status for crohn's disease treatment for children feb 13", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Shire Plc:\n* SHIRE - U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR INVESTIGATIONAL SHP647 FOR TREATMENT OF PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNâ€˜S DISEASE\n* SHIRE - HEALTH CANADA GRANTS PRIORITY REVIEW FOR INVESTIGATIONAL LANADELUMAB FOR PREVENTION OF ANGIOEDEMA ATTACKS IN OLDER PATIENTS WITH HEREDITARY ANGIOEDEMA\n* SHIRE PLC - PEDIATRIC STUDY PLANS WITH SHP647 ARE CURRENTLY UNDER DISCUSSION WITH HEALTH AUTHORITIES\n* SHIRE PLC - HEALTH CANADA REVIEW OF NDS UNDER PRIORITY REVIEW IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:08:00.000+02:00", "crawled": "2018-02-14T12:46:09.007+02:00", "highlightTitle": ""}